Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion PharmaDHA:ORIONPHARM -0.67%72 Debt-to-EBITDA is 48.21 as of Mar. 2026, which is 669% above its 10-year median of 6.27. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT20.07 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 340 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 98.24% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Orion Pharma's Debt-to-EBITDA or its related term are showing as below:
DHA:ORIONPHARM'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3 Med: 6.27 Max: 62.5
Current: 62.5
During the past 12 years, the highest Debt-to-EBITDA Ratio of Orion Pharma was 62.50. The lowest was 3.00. And the median was 6.27.
DHA:ORIONPHARM's Debt-to-EBITDA is ranked worse than 98.24% of 340
companies
in the Utilities - Independent Power Producers industry
Industry Median: 4.63
vs DHA:ORIONPHARM: 62.50
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Orion Pharma Debt-to-EBITDA Related Terms
Orion Pharma Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Debt-to-EBITDA Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Debt-to-EBITDA vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Orion Pharma (DHA:ORIONPHARM) has a Debt-to-EBITDA of 48.21 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Orion Pharma. This is 669% above median its historical median of 6.27. Over the past decade, Orion Pharma's Debt-to-EBITDA has ranged from 3.00 to 62.50. According to the industry distribution chart, Orion Pharma ranks #334 out of 340 companies in the Utilities - Independent Power Producers industry, placing it in the top 98.2%.
Is Orion Pharma's Debt-to-EBITDA too high?
Orion Pharma's current Debt-to-EBITDA of 48.21 is 669% above median its 10-year median of 6.27. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 62.50. The Utilities - Independent Power Producers industry median Debt-to-EBITDA is 4.63. Orion Pharma's value of 48.21 is 941.3% above this industry median. Based on the distribution chart, Orion Pharma ranks #334 out of 340 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Debt-to-EBITDA compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #334 out of 340 companies for Debt-to-EBITDA. This places Orion Pharma in the lower half of its industry. The industry median Debt-to-EBITDA is 4.63. Orion Pharma's value of 48.21 is 941.3% above this benchmark. Historically, Orion Pharma's own Debt-to-EBITDA has ranged from 3.00 to 62.50 over the past decade. While the company's 10-year median is 6.27 vs. the industry median of 4.63, Orion Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for an Utilities - Independent Power Producers company?
The median Debt-to-EBITDA among Utilities - Independent Power Producers companies is 4.63, based on 340 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current Debt-to-EBITDA of 48.21 is 941.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Orion Pharma. For the Utilities - Independent Power Producers industry, the median Debt-to-EBITDA is 4.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Debt-to-EBITDA is 48.21, which is 669% above median its own 10-year median of 6.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.07, compared to a current price of BDT29.50 — trading 47% above its estimated fair value. The current Debt-to-EBITDA is 48.21, which is 669% above median its 10-year median of 6.27 and 941.3% above the Utilities - Independent Power Producers industry median of 4.63. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Debt-to-EBITDA is 48.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT29.50 is trading 47% above its estimated GF Value™ of BDT20.07.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Debt-to-EBITDA: 48.21 (669% above median its 10-year median of 6.27)
GF Value™: BDT20.07 vs. price of BDT29.50 (47% above fair value)
Industry Position: 941.3% above the Utilities - Independent Power Producers median (#334 of 340)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score
Get the complete analysis for DHA:ORIONPHARM
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
